Background There is currently no licensed antiviral drug for treatment of dengue.
Chloroquine (CQ) inhibits the replication of dengue virus (DENV) in vitro. Methods and …

When we contract an infection, we typically feel sick and behave accordingly. Symptoms of
sickness behavior (SB) include anorexia, hypersomnia, depression, and reduced social …

Saharan Africa started showing resistance to this drug in late 1950s which was followed in
other parts of the World1-4. In India, the chloroquine resistance was first reported from …

Abstract Background Chloroquine (CQ), amodiaquine (AQ), and sulfadoxine‐pyrimethamine
(SP) are inexpensive drugs, but treatment failure is a problem. Combination therapy may …

Plasmodium falciparum resistance to sulfadoxine/pyrimethamine (S/P) is due to mutations in
the dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhfr) genes. Large-scale …

Background Fever is common in malaria, and drugs and sponging are widely used for
symptomatic relief. Some researchers have suggested that fever reduction may prolong …

Summary In November of 2000, Uganda changed its anti‐malarial policy to replace
chloroquine (CQ) with a combination of CQ and sulphadoxine–pyrimethamine (SP) as the …

Congo is facing frequent failures of treatment of Plasmodium falciparum malaria with
chloroquine (CQ), which is still recommended and used as a first-line drug. In Pointe-Noire …

Malaria is a leading cause of death in Sub-Saharan Africa. Tanzania changed its malaria
treatment policy from chloroquine (CQ) to Sulphadoxine-Pyrimethamine (SP) as first line …

Sulfadoxine/pyrimethamine (SP) is increasingly used against malaria in sub-Saharan Africa
because of chloroquine resistance. However, chloroquine may have a beneficial antipyretic …